

ASX / MEDIA ANNOUNCEMENT

14 April 2020

Respiri Partners with Phenix Health for wheezo® Telehealth Delivery

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is pleased to announce the signing of a Joint Development Agreement (JDA) with Phenix Health Pty Ltd (Phenix), an Australian based health workflow designer for virtual healthcare settings (telemedicine).

Under the terms of the JDA, Respiri will work to ensure that the wheezo eHealth SaaS monitoring platform is integrated into the Phenix proprietary telehealth platform, patient dashboards and asthma management plans. Phenix will be responsible for providing patients already diagnosed with asthma the option of using wheezo to help monitor their condition and so providing healthcare beyond the clinic setting.

Mr Marjan Mikel, CEO & Managing Director of Respiri said “The joint development agreement with Phenix underscores our commitment to patients with asthma and related respiratory disease in Australia during the COVID-19 pandemic. By increasing awareness and access through Phenix’s leading telehealth platform, innovative technology solutions such as wheezo will support more effective monitoring of a patient’s underlying condition to better empower patients and their treating physicians in the management of their condition during this critical period and beyond.”

Ms Gillian Alexis, Director & CEO of Phenix Health Pty Ltd commented “This ground-breaking partnership represents an improvement in quality of life for the world’s 340 million asthma sufferers and will provide primary care providers as well as respiratory specialists with new key insights to help patients manage their asthma proactively. We look forward to evolving new longitudinal models of care with Respiri that are focused on measurable outcomes by complementing traditional brick and mortar services.”

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
 CEO & Managing Director
 Respiri Limited
 P: +61 408 462 873
 E: marjan@respiri.co

Mr Nicholas Smedley
 Executive Chairman
 Respiri Limited
 P: +61 447 074 160
 E: nicholas@respiri.co

This ASX announcement dated 14 April 2020 has been authorised for release by the Board of Directors of Respiri Limited.

For personal use only

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About Phenix Health Pty Ltd

Phenix Health Pty Ltd (ACN 607 559 423) is an integrative medical tech company founded in 2015 as a spin-off from our Australia-wide after-hours home visit doctor service where it was evidenced that large sectors of the population were not able to access adequate healthcare services. Phenix worked towards developing and refining our mobile technology, remote patient monitoring and telehealth service that assists connect both health professionals to their patient. Our mobile technology includes many clinical operational features providing a powerful collaborative tool for health care providers in: clinic, aged care facilities, emergency services, hospitals and remote and mobile settings. Phenix Health solves the disconnect between vertical digital health silos. Our team has come together through years of experience in developing and operating 24/7 health care services across metro and regional. For more information, please visit <https://phenixhealth.com.au/>.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.